Now that the teams from Winterlight and Xsensio have moved into the Co-Creation and Validation stage, our expert mentors at UCB and our partner company The Bakery will be helping to co-create and then validate a clear hypothesis, one which, if proven, could make a significant impact and positively benefit patients, society and the world.
During this initial phase, we will work together in a series of workshops, helping to understand the specific benefits of the technologies developed by the startups, and which disease areas and patient journeys could see the most benefit.
At the end of Phase 1, the first group of startups will present their findings along with their UCB Champion. Those that show the biggest potential impact will then move into Phase 2, a structured 6-month partnership where we will look to help them deliver on their potential by supporting their growth plans. This could include support in creating a commercial or clinical trial, marketing and sales growth, help to secure investment or some other kind of support that will add real value.
Liam Kaufman, CEO and co-founder of Winterlight Labs, comments: “We are delighted to be working with UCB to explore how we can expand the use of our speech assessment technology in the detection and measurement of complex neurological conditions. In combining Winterlight’s expertise with UCB’s specialist knowledge and clinical and therapeutic reach, we hope to build on the opportunities for our platform to support digitized healthcare and research strategies, and ultimately make our technology an option for the monitoring of more conditions and more patients globally.”
Esmeralda Megally, CEO of Xsensio says: “We’re super-excited to be working with UCB to explore how our technology can help patients and clinicians dealing with challenging diseases both diagnose and monitor these difficult conditions better. Together we feel sure we can make a big difference to people’s quality of life.”